Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study.

JRSM Open Pub Date : 2025-03-19 eCollection Date: 2025-03-01 DOI:10.1177/20542704251325314
Joel Lexchin
{"title":"Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study.","authors":"Joel Lexchin","doi":"10.1177/20542704251325314","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Investigate the additional therapeutic value compared to existing medicines of new oncology drugs given a conditional approval (Notice of Compliance with conditions, NOC/c) by Health Canada using therapeutic ratings from four independent organisations.</p><p><strong>Design: </strong>A list of all new oncology drugs with an NOC/c from the start of the programme in 1998 to the end of 2023 was constructed. First-in-class and orphan drug status was determined for all drugs. Therapeutic ratings were obtained from the Canadian Patented Medicine Prices Review Board, the French drug bulletin Prescrire International, the French agency Haute Autorité de Santé and the German Institute for Quality and Efficiency in Health Care. If more than one organisation rated the drug, the highest rating was used.</p><p><strong>Setting: </strong>Canada.</p><p><strong>Participants: </strong>Oncology drugs with a conditional approval.</p><p><strong>Main outcome measures: </strong>Additional therapeutic gain compared to existing products.</p><p><strong>Results: </strong>Fifty-four oncology drugs were approved. Conditions were fulfilled for 29, fulfilment was still pending for 22 and 3 drugs were either discontinued by the manufacturer or placed on restricted access. Eighteen drugs had both orphan drug and first-in-class status. Therapeutic evaluations were available for 50 drugs, and the distribution of additional therapeutic value was examined for the entire group of 50 drugs, for 29 drugs that had fulfilled their conditions and for 18 drugs with both orphan drug and first-in-class status. In the three groups, 8.0%, 10.3% and 11.7%, respectively, offered major therapeutic improvement.</p><p><strong>Conclusions: </strong>Few new oncology drugs approved through the NOC/c pathway offer major therapeutic improvements over existing drugs.</p>","PeriodicalId":17674,"journal":{"name":"JRSM Open","volume":"16 3","pages":"20542704251325314"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924082/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JRSM Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20542704251325314","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Investigate the additional therapeutic value compared to existing medicines of new oncology drugs given a conditional approval (Notice of Compliance with conditions, NOC/c) by Health Canada using therapeutic ratings from four independent organisations.

Design: A list of all new oncology drugs with an NOC/c from the start of the programme in 1998 to the end of 2023 was constructed. First-in-class and orphan drug status was determined for all drugs. Therapeutic ratings were obtained from the Canadian Patented Medicine Prices Review Board, the French drug bulletin Prescrire International, the French agency Haute Autorité de Santé and the German Institute for Quality and Efficiency in Health Care. If more than one organisation rated the drug, the highest rating was used.

Setting: Canada.

Participants: Oncology drugs with a conditional approval.

Main outcome measures: Additional therapeutic gain compared to existing products.

Results: Fifty-four oncology drugs were approved. Conditions were fulfilled for 29, fulfilment was still pending for 22 and 3 drugs were either discontinued by the manufacturer or placed on restricted access. Eighteen drugs had both orphan drug and first-in-class status. Therapeutic evaluations were available for 50 drugs, and the distribution of additional therapeutic value was examined for the entire group of 50 drugs, for 29 drugs that had fulfilled their conditions and for 18 drugs with both orphan drug and first-in-class status. In the three groups, 8.0%, 10.3% and 11.7%, respectively, offered major therapeutic improvement.

Conclusions: Few new oncology drugs approved through the NOC/c pathway offer major therapeutic improvements over existing drugs.

加拿大卫生部有条件批准的肿瘤产品的治疗价值:横断面研究。
目标:利用四家独立机构的治疗评级,调查加拿大卫生部有条件批准(符合条件通知,NOC/c)的新型肿瘤药物与现有药物相比的额外治疗价值:设计:建立了一份从 1998 年该计划开始到 2023 年底所有获得 NOC/c 批准的肿瘤新药清单。确定了所有药物的一类药和孤儿药地位。治疗评级来自加拿大专利药品价格审查委员会(Canadian Patented Medicine Prices Review Board)、法国药品公报《国际处方集》(Prescrire International)、法国卫生高级管理局(Haute Autorité de Santé)和德国医疗质量与效率研究所(German Institute for Quality and Efficiency in Health Care)。如果有多个机构对药物进行评级,则以最高评级为准:地点:加拿大:有条件批准的肿瘤药物:与现有产品相比的额外治疗收益:结果:54 种肿瘤药物获得批准。结果:54 种肿瘤药物获得批准,其中 29 种符合条件,22 种尚未符合条件,3 种药物被生产商停产或限制使用。有 18 种药物既是孤儿药,又是一类药物。对 50 种药物进行了治疗评价,并对整个 50 种药物组、29 种已满足条件的药物和 18 种既是孤儿药又是一类药的药物的额外治疗价值分布情况进行了研究。在这三组药物中,分别有 8.0%、10.3% 和 11.7%的药物具有重大治疗效果:结论:通过 NOC/c 途径获批的肿瘤新药与现有药物相比,在治疗方面几乎没有重大改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
期刊介绍: JRSM Open is a peer reviewed online-only journal that follows the open-access publishing model. It is a companion journal to the Journal of the Royal Society of Medicine. The journal publishes research papers, research letters, clinical and methodological reviews, and case reports. Our aim is to inform practice and policy making in clinical medicine. The journal has an international and multispecialty readership that includes primary care and public health professionals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信